Juno CEO quietly steps down after $9 billion Celgene acquisition

Hans Bishop said Tuesday that he recently left the CEO role and joined Celgene's board of directors. Bishop had led Juno since it spun out of the Fred Hutchinson Cancer Research Center in 2013.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news